677 related articles for article (PubMed ID: 25554016)
1. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
Qazi AK; Hussain A; Khan S; Aga MA; Behl A; Ali S; Singh SK; Taneja SC; Shah BA; Saxena AK; Mondhe DM; Hamid A
Cancer Lett; 2015 Apr; 359(1):47-56. PubMed ID: 25554016
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway.
Li A; Wang J; Wu M; Zhang X; Zhang H
Eur J Pharmacol; 2015 Jan; 747():71-87. PubMed ID: 25498792
[TBL] [Abstract][Full Text] [Related]
3. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
4. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
5. Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.
Tarrado-Castellarnau M; Cortés R; Zanuy M; Tarragó-Celada J; Polat IH; Hill R; Fan TW; Link W; Cascante M
Pharmacol Res; 2015 Dec; 102():218-34. PubMed ID: 26375988
[TBL] [Abstract][Full Text] [Related]
6. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
7. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
8. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
[TBL] [Abstract][Full Text] [Related]
9. M
Peng Y; Qiu L; Xu D; Zhang L; Yu H; Ding Y; Deng L; Lin J
Life Sci; 2017 Sep; 185():63-72. PubMed ID: 28751160
[TBL] [Abstract][Full Text] [Related]
10. Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells.
Izutani Y; Yogosawa S; Sowa Y; Sakai T
Int J Oncol; 2012 Mar; 40(3):816-24. PubMed ID: 22307336
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
12. Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death.
Zhu L; Derijard B; Chakrabandhu K; Wang BS; Chen HZ; Hueber AO
Cancer Lett; 2014 Nov; 354(2):355-64. PubMed ID: 25199763
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y
Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057
[TBL] [Abstract][Full Text] [Related]
16. Marine lipopeptide Iturin A inhibits Akt mediated GSK3β and FoxO3a signaling and triggers apoptosis in breast cancer.
Dey G; Bharti R; Dhanarajan G; Das S; Dey KK; Kumar BN; Sen R; Mandal M
Sci Rep; 2015 May; 5():10316. PubMed ID: 25974307
[TBL] [Abstract][Full Text] [Related]
17. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
19. T63, a new 4-arylidene curcumin analogue, induces cell cycle arrest and apoptosis through activation of the reactive oxygen species-FOXO3a pathway in lung cancer cells.
Liu H; Zhou BH; Qiu X; Wang HS; Zhang F; Fang R; Wang XF; Cai SH; Du J; Bu XZ
Free Radic Biol Med; 2012 Dec; 53(12):2204-17. PubMed ID: 23085518
[TBL] [Abstract][Full Text] [Related]
20. FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells.
Liu H; Yin J; Wang C; Gu Y; Deng M; He Z
Anticancer Drugs; 2014 Sep; 25(8):898-907. PubMed ID: 24814195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
